MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-02-2026
Twist Bioscience Corporation Retained Earnings 2011-2026 | TWST
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Twist Bioscience Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.32 B | -1.24 B | -1.03 B | -828 M | -611 M | -458 M | -319 M | -211 M | -140 M | -80.3 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -80.3 M | -1.32 B | -624 M |
Quarterly Retained Earnings Twist Bioscience Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.35 B | -1.32 B | -1.29 B | -1.31 B | -1.27 B | -1.24 B | -1.21 B | -1.12 B | -1.08 B | -1.03 B | -987 M | -929 M | -870 M | -828 M | -777 M | -717 M | -656 M | -611 M | -569 M | -611 M | -491 M | -458 M | -458 M | -458 M | -374 M | -319 M | -319 M | -319 M | -233 M | -211 M | -211 M | -211 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -211 M | -1.35 B | -745 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 18.56 | 10.74 % | $ 196 M |  China |
 |
Agilent Technologies
A
|
348 M | - | - | $ 34.4 B |  USA |
 |
Castle Biosciences
CSTL
|
-224 M | $ 18.88 | 4.02 % | $ 547 M | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.19 | 1.44 % | $ 490 M | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.8 | -5.26 % | $ 7.96 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
-735 M | $ 20.49 | -0.58 % | $ 1.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 419.17 | -1.08 % | $ 12.1 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-166 M | - | - | $ 9.42 M |  Israel |
 |
Lantheus Holdings
LNTH
|
680 M | - | - | $ 6.5 B | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 041.91 | 1.75 % | $ 21.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 3.62 | -2.95 % | $ 335 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.63 | 1.87 % | $ 2.17 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.36 | 1.21 % | $ 1.07 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 18.93 | 1.39 % | $ 424 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 196.91 | 0.81 % | $ 19.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 159.12 | -2.29 % | $ 7.89 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Personalis
PSNL
|
-631 M | $ 6.71 | 5.01 % | $ 599 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 98.66 | 0.19 % | $ 12.4 B | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 5.82 | 5.82 % | $ 243 M | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 117.09 | -0.25 % | $ 9.66 B |  Irlanda |
 |
Illumina
ILMN
|
-1.24 B | $ 143.24 | -1.21 % | $ 22.8 B | USA |
 |
Soleno Therapeutics
SLNO
|
-431 M | $ 52.99 | 0.08 % | $ 2.69 B | USA |
 |
Trinity Biotech plc
TRIB
|
-79.1 M | $ 0.58 | -1.08 % | $ 208 M | Irlanda |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.41 | 7.11 % | $ 5.54 M | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 448.21 | 0.49 % | $ 169 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 254.02 | -0.16 % | $ 21.1 B | USA |
 |
Waters Corporation
WAT
|
10.4 B | $ 333.21 | -0.51 % | $ 19.8 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 134.72 | 8.23 % | $ 6.3 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-536 M | $ 8.43 | -2.99 % | $ 1.83 B | USA |